India Manufacturing Growth Slows to Five-Year Low in August 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Dollar Hits Two-Week High as Iran Conflict Lifts Oil and Bond Yields 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Asian Stocks Slip as Fed Rate Hike Bets and Oil Surge Weigh 
Asian Currencies Mixed as Yen Nears 160, Oil Surges 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Bessent Urges Japan on Fiscal Discipline, BOJ Rate Hikes 
Australia GDP Beats Forecast, Boosting RBA Rate Hike Bets 
Oil Prices Rise as U.S.-Iran Fighting Fuels Supply Fears 
Treasury Yields Set to Stay High as Debt Supply Pressures Bond Market 
Trump Signs Order to Cut Routine Childhood Vaccines 
German Retail Sales Drop 3.4% in July 
Asian Currencies Weaken as Dollar Rises, Kiwi Slides After RBNZ Hike 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Add as a preferred source on Google
Samsung Biologics, South Korea's biotech behemoth, expands its portfolio in a $1.08 billion deal with U.S. pharma titan, Pfizer, marking a landmark in global biotech manufacturing. The enhanced partnership will leverage Samsung's newest facility to produce Pfizer's multiproduct biosimilar portfolio.
This includes a new contract signed with Pfizer, building upon the initial deal established in March. Under the new agreement, Samsung Biologics will manufacture an additional $193 million of Pfizer products.
Additionally, Samsung Biologics will produce Pfizer's multiproduct biosimilar portfolio, encompassing oncology, inflammation, and immunotherapy, with a value of $704 million. The company will extend its manufacturing capabilities to provide Pfizer ample capacity for large-scale production of a multiproduct biosimilar portfolio.
This strategic collaboration will occur at Samsung Biologics' newest facility, Plant 4, in Songdo, South Korea. Completing the 240,000-liter biomanufacturing plant in June 2023 marks a significant milestone in the continued growth of Samsung Biologics.
Mike McDermott, Chief Global Supply Officer and Executive Vice President at Pfizer, expressed his enthusiasm for the partnership, stating they are pleased to extend the strategic collaboration with Pfizer as we share and support their strong vision to bring innovative solutions for patients around the globe.
These manufacturing partnerships solidify Samsung Biologics' position in the global contract development and manufacturing organization (CDMO) market. As part of its expansion strategy, the company is increasing its production capacity and aims to become a major player in the industry.
The contracts with Pfizer highlight the long-term strategic partnership between the two companies, further establishing Samsung Biologics as a trusted collaborator. The company plans to explore new avenues in overseas markets by considering opening new sales offices to facilitate communication with global customers. With an existing office in New Jersey and a research and development center in San Francisco, Samsung Biologics is set for continued growth on a global scale.
